# IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

> **NCT00406367** · PHASE3 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 109 (actual)

## Conditions studied

- Blepharospasm

## Interventions

- **DRUG:** incobotulinumtoxinA (Xeomin)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00406367
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-04
- **Final completion:** 2009-07
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2013-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406367, "IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00406367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*